Skip to main content

Table 4 Proliferative response of PBMC to PPD and BCG

From: Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis

  Lymphocyte Proliferation—counts per minute (stimulation index)
  Thalidomide Placebo
  HIV+ CPM (SI) HIV CPM (SI) HIV+/ CPM (SI)
Controls:    
pre 704 ± 337 1239 ± 1028 1037 ± 524
mid 2264 ± 4694 2620 ± 2949 1158 ± 664
post 1487 ± 1694 1140 ± 664 1632 ± 1376
PPD:    
pre 38253 ± 38987 57926 ± 41427 51878 ± 33764
  (60 ± 64) (64 ± 46) (63 ± 50)
mid 49341 ± 46031 44717 ± 23963 60007 ± 28475
  (52 ± 56) (34 ± 31) (80 ± 75)
post 44077 ± 43822 53078 ± 31411 52682 ± 43678
  (56 ± 61) (59 ± 44) (63 ± 52)
BCG:    
pre 32879 ± 36725 22096 ± 28567 26777 ± 18977
  (42 ± 37) (28 ± 36) (32 ± 26)
mid 44767 ± 54076 23788 ± 17519 34200 ± 29931
  (42 ± 58) (23 ± 32) (42 ± 53)
post 40172 ± 42663 23259 ± 17060 27891 ± 32902
  (43 ± 50) (26 ± 19) (33 ± 36)
  1. Results are means ± one standard deviation (SD) of counts per minute (stimulation indexes) of proliferative responses to antigen stimulation of PBMC tested before (pre), during (mid), and 5 days after (post) treatment with thalidomide or placebo (see Table 1). No significant changes were observed.